 | Up a level |
Journal Article
Drilon, Alexander, Siena, Salvatore, Dziadziuszko, Rafal 
ORCID: 0000-0001-8080-9843, Barlesi, Fabrice, Krebs, Matthew G., Shaw, Alice T., de Braud, Filippo, Rolfo, Christian, Ahn, Myung-Ju, Wolf, Juergen, Seto, Takashi, Cho, Byoung Chul, Patel, Manish R., Chiu, Chao-Hua, John, Thomas, Goto, Koichi, Karapetis, Christos S., Arkenau, Hendrick-Tobias, Kim, Sang-We, Ohe, Yuichiro, Li, Yu-Chung, Chae, Young K., Chung, Christine H., Otterson, Gregory A., Murakami, Haruyasu, Lin, Chia-Chi, Tan, Daniel S. W., Prenen, Hans, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R. and Doebele, Robert C.
(2020).
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol., 21 (2).
S. 261 - 271.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Heist, Rebecca Suk, Garon, Edward B., Tan, Daniel Shao-Weng, Groen, Harry J. M., Seto, Takashi, Smit, Egbert F., Zou, Mike R., Yang, Yiqun, Li, Ying, Chassot-Agostinho, Andrea and Wolf, Juergen (2021). Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Kim, Dong-Wan, Tan, Daniel Shao-Weng, Aix, Santiago Ponce, Sequist, Lecia V., Smit, Egbert F., Hida, Toyoaki, Yang, James Chih-Hsin, Felip, Enriqueta, Seto, Takashi, Grohe, Christian, Wolf, Juergen, Ko, Jinnie, Diallo, Mariama, Pultar, Philippe, Giovannini, Monica and Kim, Sang-We (2018). Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Tan, Daniel S-W, Leighl, Natasha B., Riely, Gregory J., Yang, James C-H, Sequist, Lecia, V, Wolf, Juergen, Seto, Takashi, Felip, Enriqueta, Aix, Santiago P., Jonnaert, Maud, Pan, Chun, Tan, Eugene Y., Ko, Jinnie, Moody, Susan E. and Kim, Dong-Wan (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Resp. Med., 8 (6). S. 561 - 573. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600
Tan, Daniel Shao-Weng, Yang, James Chih-Hsin, Leighl, Natasha B., Riely, Gregory J., Sequist, Lecia V., Felip, Enriqueta, Seto, Takashi, Wolf, Juergen, Moody, Susan Elizabeth, Adams, Kenneth, Schmitz, Shu-Fang Hsu, Tan, Eugene Y. and Kim, Dong-Wan (2016). Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Wolf, Juergen, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B., Groen, Harry J. M., Tan, Daniel S. W., Hida, Toyoaki, de Jonge, Maja, Orlov, Sergey V., Smit, Egbert F., Souquet, Pierre-Jean, Vansteenkiste, Johan, Hochmair, Maximilian, Felip, Enriqueta, Nishio, Makoto, Thomas, Michael, Ohashi, Kadoaki, Toyozawa, Ryo, Overbeck, Tobias R., de Marinis, Filippo, Kim, Tae-Min, Laack, Eckart, Robeva, Anna, Le Mouhaer, Sylvie, Waldron-Lynch, Maeve, Sankaran, Banu, Balbin, O. Alejandro, Cui, Xiaoming, Giovannini, Monica, Akimov, Mikhail and Heist, Rebecca S. (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (10). S. 944 - 958. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406